|Outcome||Relative effect 95%CI||LoD||Trt. better when||I2||k (RCT/OBS)||Bayesian probability||Overall ROB||Publication bias||Degree of certainty||Endpoint importance||Published MA|
|clinical deterioration||0.07 [0.00, 1.26]||< 1||0%||1 study (1/-)||96.3 %||some concern||not evaluable||moderate||important||-|
|serious adverse events||0.17 [0.02, 1.49]||< 1||0%||1 study (1/-)||94.4 %||some concern||not evaluable||moderate||important||-|
|adverse events||0.98 [0.40, 2.38]||< 1||0%||1 study (1/-)||51.9 %||some concern||not evaluable||moderate||non important||-|
LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.